Pooling 4,805 people with type 2 diabetes, researchers saw about 8% weight loss at both doses, with more stomach side effects and dropouts at 2.4 mg.
Recap by typeshit. Full story at bioengineer.org.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The study's lead author told Newsweek the team found a benefit that reaches past what GLP-1 drugs are usually known for.
A study puts first-year GLP-1 discontinuation somewhere between a fifth and half of patients. The source shared the figure without naming the study.
Loading…